Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)
Gertz, Morie A.
Kaminer, Lynne S.
Vesole, David H.
Greipp, Philip R.
MetadataShow full item record
Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.
Is part ofLeukemia & Lymphoma, 2004, vol. 45, núm. 10, p. 2047-2055
European research projects
Showing items related by title, author, creator and subject.
Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group Cleeland, C. S.; Portenoy, R. K.; Rué i Monné, Montserrat; Mendoza, T. R.; Weller, E.; Payne, R.; Kirshner, J.; Atkins, J. N.; Johnson, P. A.; Marcus, A. (Oxford University Press, 2005)Background: Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology ...
Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants Ma, Julian K-C.; Drossard, Jürgen; Lewis, David; Altmann, Friedrich; Boyle, Julia; Christou, Paul; Cole, Tom; Dale, Philip; van Dolleweerd, Craig J.; Isitt, Valerie; Katinger, Dietmar; Lobedan, Martin; Mertens, Hubert; Paul, Mathew; Rademacher, Thomas; Sack, Markus; Hundleby, Penelope A. C.; Stiegler, Gabriela; Stöger, Eva; Twyman, Richard M.; Vcelar, Brigitta; Fischer, Rainer (Wiley, 2015)Although plant biotechnology has been widely investigated for the production of clinical-grade monoclonal antibodies, no antibody products derived from transgenic plants have yet been approved by pharmaceutical regulators ...
Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study Arroyo, David; Betriu i Bars, M. Àngels; Martínez Alonso, Montserrat; Vidal Amat, Teresa; Valdivielso Revilla, José Manuel; Fernández i Giráldez, Elvira (BioMed Central, 2014)Background: Cardiovascular events (CVE) are more prevalent in chronic kidney disease (CKD) than in general population, being the main cause of morbimortality. Specific risk factors related to CKD have been suggested, because ...